Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16263344 | 1.00 | CYP46A1 (0.36) | CYP46A1BACE1RAB9AGRIN2BESR2 | |
| SCHEMBL16263339 | 0.91 | BACE1 (0.41) | CYP46A1BACE1RAB9AGRIN2BESR2 | |
| SCHEMBL16263343 | 0.86 | HTT (0.43) | BACE1RAB9AGRIN2BESR2NPSR1 | |
| SCHEMBL20192211 | 0.86 | HTT (0.43) | BACE1RAB9AGRIN2BESR2NPSR1 | |
| SCHEMBL16263348 | 0.78 | MEN1 (0.39) | RAB9AL3MBTL1LMNAHTTMEN1 | |
| SCHEMBL15079018 | 0.68 | HTT (0.38) | BACE1RAB9AL3MBTL1LMNAHTT | |
| SCHEMBL16263338 | 0.65 | TDP1 (0.37) | RAB9ANPSR1L3MBTL1LMNAHTT | |
| SCHEMBL16263342 | 0.64 | HTT (0.32) | RAB9AHTTMEN1KMT2APOLB | |
| SCHEMBL16263337 | 0.61 | SRD5A1 (0.36) | RAB9AL3MBTL1LMNAHTTMEN1 | |
| SCHEMBL15700144 | 0.60 | HTT (0.49) | BACE1NPSR1L3MBTL1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013096971-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | GFPT1, NUDT1, INF2 | CYP46A1 2254/4885BACE1 4026/4885RAB9A 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.